Hormone Replacement Therapy Market

Industry Insights-

• The Global Hormone Replacement Therapy Market was valued at USD 21.04 Billion in 2020
• It is anticipated to reach USD 36.54 Billion by 2027
• A CAGR of 8.20% is anticipated over the forecast period

Overview-

Hormone replacement therapy is a treatment used to release symptoms of the menopause. The main advantage is that it is a very effective method of controlling menopausal symptoms, and it can make an important difference to a woman’s quality of life and security. Hormone replacement therapy can also reduce a woman’s risk of developing osteoporosis and cancer of the colon and rectum. Additionally, hormones are secreted predominantly from the endocrine glands and absorbed into the bloodstream.

The hormones that have been most commonly utilized in hormone replacement therapy are progesterone, estrogen, testosterone, adrenal hormones, DHEA, thyroid hormones, pregnenolone, melatonin, and human growth hormone. It is the most effective treatment for menopause symptoms. Systemic hormone replacement therapy helps in treating cancer, rheumatoid arthritis and other diseases. Moreover, this treatment is particularly favorable for patients with growth hormone deficiency, women nearing menopause and elderly people suffering from hypogonadism. It may also protect against osteoporosis.

Covid-19 Impact-

The hormone replacement therapy market is experiencing an upsurge due to the increasing prevalence of thyroid conditions and the availability of long-acting hGH products. The American Thyroid Association estimates that 12.0% of the U.S. population will suffer from thyroid problems during their lifetime, while 20.0 million Americans already have some form of the condition. Furthermore, research has suggested that individuals receiving HRT therapy may have a reduced risk of COVID-19 infection and mortality.

Key Players-

Some of the key players for global Hormone Replacement Therapy Market are-

• Abbott Laboratories
• Novo Nordisk
• Novartis
• Bayer Healthcare
• Eli Lilly
• Mylan Laboratories
• Roche
• Genentech
• Orion Pharma AB
• Allergen Plc
• AbbVie Inc
• Merck KGaA
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceuticals
• Endo International
• Sun Pharmaceutical Industries Ltd
• others

Segmentation Analysis-

By Product:

• Estrogen Replacement Therapy
• Human Growth Hormone Replacement Therapy
• Thyroid Replacement Therapy
• Testosterone Replacement Therapy

Based on product, the hormone replacement therapy market is segmented into estrogen replacement therapy, human growth hormone replacement therapy, thyroid replacement therapy, testosterone replacement therapy, parathyroid hormone replacement, and testosterone replacement therapy. The market share of the estrogen and progesterone replacement therapy segment was the highest, due to its popularity among women going through menopause. According to the American Congress of Obstetricians and Gynecologists, approximately 6,000 women enter menopause every day in the U.S., thus driving the demand for such therapies.

The parathyroid hormone replacement segment is anticipated to experience the fastest growth over the forecast period due to growing incidence of hypoparathyroidism and increasing product penetration. According to the National Organization for Rare Diseases 2021 database, approximately 70,000 people in the U.S. are living with hypoparathyroidism. In the parathyroid hormone segment, only one product has been approved, Natpara.

By Administration:

• Oral
• Parenteral
• Transdermal

On the basis of administration, the global market is classified as oral, parenteral, and transdermal. The growth of the hormone replacement therapy market is driven by an increase in the number of people suffering from hormone-related disorders, such as menopause in women and hypogonadism in men. Additionally, the availability of advanced therapeutic options such as pen-based delivery, oral tablets, and injections is expected to fuel the growth of the market.

The launch of NGENLA is anticipated to drive the growth of the global market as it reduces the frequency of injections and is expected to improve patient adherence to treatment. Furthermore, the product is expected to help reduce the cost of treatments in the long run, as it requires fewer injections. This, in turn, is expected to drive the growth of the hormone replacement therapy market.

By Disease:

• Menopause
• Hypothyroidism
• Male Hypothyroidism
• Growth Hormone Deficiency
• Cancer
• Others

The global hormone replacement therapy market based on disease type has been segmented into menopause, male hypogonadism, cancer, growth hormone deficiency, hypothyroidism, and hypoparathyroidism. The menopause segment held the largest share of the market. This is due to the growing prevalence of menopause among women worldwide.

The hypoparathyroidism segment is projected to experience significant growth during the forecast period due to the introduction of novel treatments and products. For example, in September 2020, Ascendis Pharma A/S presented TransCon technologies at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting, and released the top-line results of the phase 2 clinical trial for TransCon PTH. The drug is currently undergoing phase 3 clinical trials, and its approval and launch would provide more parathyroid hormone replacement options.

By Regional & Country Analysis:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

North America is expected to dominate the global hormone replacement therapy market due to the increasing awareness about the hormonal replacement therapy And Increasing number of women’s which have menopause problems in this region.  For example, National Center for Biotechnology Information, in the United States, approximately 1.3 million women become menopausal each year and, 1% of women experience premature menopause before the age of 40. The Asia Pacific is expected to experience surge of demand too, owing to the factors such as increased awareness levels among the end users and improving healthcare infrastructure. Rising geriatric population is one of the primary factors responsible for the growth of the hormonal replacement therapy market in the Europe.

Market Drivers-

Growing awareness about hormone replacement

Increasing healthcare expenditure due to growing awareness about health related problems. For example, According to OECD, the US spent $10,209 on healthcare per capita, or per person, in 2017. That is more than any other country in OECD's 36-country consortium, and over $2,000 more than Switzerland, the second-highest spending country. In addition, rising drug development and hormonal imbalance disorders with rising geriatric population are also boosting the hormone replacement therapy market growth.

Additionally, the rising women’s population between the age group of 45 to 60, which increases the range of menopausal window due to this factor the demand of hormonal replacement therapy, is also growing. However, the hormone replacement therapy has number of side effects which may hamper the market growth. For example, fluid retention, indigestion, headache, and depression, bloating, swelling, nausea, leg cramps. Combined hormone replacement therapy slightly increases the risk of developing breast cancer, womb cancer, ovarian cancer and stroke.

For example, Women who take hormone replacement therapy for more than 1 year have a higher risk of breast cancer than women who never use hormone replacement therapy. The risk is linked to all types of hormone replacement therapy except vaginal estrogen. In spite of that, technological advancements in this field may create the number of opportunities within the forecast period.

Increasing participation of major players in the development of new therapies

The introduction of SKYTROFA is an example of the increasing involvement of key players in the development of novel therapies, which is resulting in new products entering the market. This product is the first once-weekly treatment for growth hormone deficiency in the pediatric population and was approved by the European Commission in January 2022. With this approval, Ascendis Pharma A/S has made a major advancement in the treatment of growth hormone disorders among children and adolescents.

Recent Developments-

• September 12th, 2017; after a massive study of hormone replacement therapy was halted due to higher rates of breast cancer, heart attack and stroke among women assigned to the drugs to treat menopausal symptoms, a new follow-up study has found those women had no higher risk of death as of 2014 than participants who took a placebo.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2020:	USD 21.04 Billion
Base year considered	2021
Forecast Period CAGR %:	8.20%
Market Size Expected in 2027:	USD 36.54 Billion
Tables, Charts & Figures:	175
Pages	300
Companies	Abbott Laboratories, Novo Nordisk, Novartis, Bayer Healthcare, Eli Lilly, Mylan Laboratories, Roche, Genentech, Orion Pharma AB, Allergen Plc , AbbVie Inc, Merck KGaA, F. Hoffmann-La Roche Ltd., Teva Pharmaceuticals, Endo International, Sun Pharmaceutical Industries Ltd, others.
Segments Covered	By Product, By Administration, By Disease
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa